Evidence map›Paper›PMID 29703864›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.

Jennifer M Bratt, Kevin Y Chang, Michelle Rabowsky, Lisa M Franzi, Sean P Ott, Simone Filosto, Tzipora Goldkorn, Muhammad Arif, Jerold A Last, Nicholas J Kenyon and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. PI3KFrontiers in immunology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jennifer M BrattDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.ORCID 0000-0001-9660-5634
Kevin Y ChangDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.ORCID 0000-0001-7477-5763
Michelle RabowskyDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.
Lisa M FranziDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.ORCID 0000-0003-4181-277X
Sean P OttDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.ORCID 0000-0001-8792-7236
Simone FilostoDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.
Tzipora GoldkornDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.
Muhammad ArifDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.
Jerold A LastDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.
Nicholas J KenyonDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817.
Amir A ZekiDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817; aazeki@ucdavis.edu.
University of California, Davis · US

Funding

Western Center for Agricultural Health and SafetyU54OH007550 · OH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FATHALLAH, FADI A · 2011 to 2025
$27.5M
UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
TRAINING IN COMPARATIVE LUNG BIOLOGY AND MEDICINET32HL007013 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI Elena Goncharova, Nicholas J. KENYON · 1985 to 2026
$10.1M
UC Davis Clinical and Translational Science CenterKL2RR024144 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2006 to 2011
$3.1M
MOLECULAR CHARACTERIZATION OF A LUNG SPHINGOMYELINASER01HL066189 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI GOLDKORN, TZIPORA · 2001 to 2013
$2.7M
L-arginine as a therapy in severe asthmaR01HL105573 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J. · 2012 to 2016
$1.9M
The Modulation of Eotaxin Expression by Statins: Implications for Asthma TherapyK08HL114882 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2014 to 2016
$435k
ACL HHS U54OH007550NCRR NIH HHS KL2 RR024144NHLBI NIH HHS K08 HL114882NHLBI NIH HHS R01 HL066189NHLBI NIH HHS R01 HL105573NHLBI NIH HHS T32 HL007013NIOSH CDC HHS U54 OH007550
6 · The paper itself

Abstract

Ras, a small GTPase protein, is thought to mediate Th2-dependent eosinophilic inflammation in asthma. Ras requires cell membrane association for its biological activity, and this requires the posttranslational modification of Ras with an isoprenyl group by farnesyltransferase (FTase) or geranylgeranyltransferase (GGTase). We hypothesized that inhibition of FTase using FTase inhibitor (FTI)-277 would attenuate allergic asthma by depleting membrane-associated Ras. We used the OVA mouse model of allergic inflammation and human airway epithelial (HBE1) cells to determine the role of FTase in inflammatory cell recruitment. BALB/c mice were first sensitized then exposed to 1% OVA aerosol or filtered air, and half were injected daily with FTI-277 (20 mg/kg per day). Treatment of mice with FTI-277 had no significant effect on lung membrane-anchored Ras, Ras protein levels, or Ras GTPase activity. In OVA-exposed mice, FTI-277 treatment increased eosinophilic inflammation, goblet cell hyperplasia, and airway hyperreactivity. Human bronchial epithelial (HBE1) cells were pretreated with 5, 10, or 20 μM FTI-277 prior to and during 12 h IL-13 (20 ng/ml) stimulation. In HBE1 cells, FTase inhibition with FTI-277 had no significant effect on IL-13-induced STAT6 phosphorylation, eotaxin-3 peptide secretion, or Ras translocation. However, addition of exogenous FPP unexpectedly augmented IL-13-induced STAT6 phosphorylation and eotaxin-3 secretion from HBE1 cells without affecting Ras translocation. Pharmacological inhibition of FTase exacerbates allergic asthma, suggesting a protective role for FTase or possibly Ras farnesylation. FPP synergistically augments epithelial eotaxin-3 secretion, indicating a novel Ras-independent farnesylation mechanism or direct FPP effect that promotes epithelial eotaxin-3 production in allergic asthma.

Indexed as

AnimalsAsthmaBronchiBronchial HyperreactivityDisease Models, AnimalEnzyme InhibitorsEosinophilsEpithelial CellsFarnesyltranstransferaseHumansInflammationLungMaleMethionineMiceMice, Inbred BALB CEnzyme Inhibitorsfarnesyl pyrophosphateFarnesyltranstransferaseFTI 277MethionineOvalbuminPolyisoprenyl Phosphatesras ProteinsSesquiterpenes

Identifiers

PMID29703864
PMCPMC5964018
OpenAlexW2801359044

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.